Published in final edited form as:

J Am Chem Soc. 2017 October 04; 139(39): 13944–13949. doi:10.1021/jacs.7b08496.

Sequential Ruthenium Catalysis for Olefin Isomerization and Oxidation: Application to the Synthesis of Unusual Amino Acids

Marc Liniger[†], Yiyang Liu, and Brian M. Stoltz^{*}

Warren and Katherine Schlinger Laboratory for Chemistry and Chemical Engineering, Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, United States

Abstract

How can you use a ruthenium isomerization catalyst twice? A ruthenium-catalyzed sequence for the formal two-carbon scission of allyl groups to carboxylic acids has been developed. The reaction includes an initial isomerization step using commercially available ruthenium catalysts followed by *in situ* transformation of the complex to a metal-oxo species, which is capable of catalyzing subsequent oxidation reactions. The method enables enantioselective syntheses of challenging α -tri- and tetrasubstituted α -amino acids including an expedient total synthesis of the antiepileptic drug levetiracetam.

SYNOPSIS TOC

If you are submitting your paper to a journal that requires a synAuthors are required to submit a graphic entry for the Table of Contents (TOC) that, in conjunction with the manuscript title, should give the reader a representative idea of one of the following: A key structure, reaction, equation, concept, or theorem, etc., that is discussed in the manuscript. Consult the journal's Instructions for Authors for TOC graphic specifications.

INTRODUCTION

The use of a single metal catalyst for several chemical transformations in a one-pot and/or a sequential manner¹ is highly desirable due to high material cost and limited resources of

^{*}Corresponding Author: stoltz@caltech.edu.

[†]Present Address: Givaudan Schweiz AG, Fragrances S&T / Ingredients Research, Ueberlandstrasse 138, CH-8600 Dübendorf, Switzerland

ASSOCIATED CONTENT

Experimental procedures, characterization data, and crystallographic information files. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Notes

The authors declare no competing financial interest.

transition metals.² Moreover, new tools for modifying prevalent functional groups, which are easily installed in a chemo- and stereoselective fashion, are needed to expand the application of novel methodology in both academic and industrial settings.³ In this context, allyl groups are ubiquitous and their introduction is very well established including asymmetric additions.⁴ In general, three modes for their installation can be distinguished (Figure 1): As a nucleophile^{5,6} (*e.g.* Grignard addition⁷), as an electrophile⁸ (*e.g.* Tsuji-Trost allylation⁹) or as a formally neutral species¹⁰ (*e.g.* Keck radical allylation¹¹).

Most of these methods not only find widespread use in organic synthesis, but also allow for the installation of allyl groups in a highly stereoselective fashion, even to build challenging chiral quaternary stereocenters.¹² However, tools for the formal scission of two carbons of an allyl group leading to a truncated carboxylic acid using a single transition metal catalyst have, to our knowledge, not been described (Scheme 1A, $M_1=M_2$). The use of only one catalyst is in strong contrast to the field of one-pot catalysis, where for instance two transition metal catalysts are used for isomerization/metathesis reactions.¹³

Although a sequence involving vinylation followed by oxidative cleavage of the double bond would in theory lead to the same carboxylic acid product, asymmetric vinylation reactions are far less established than allylations (Scheme 1B).⁴ In particular, catalytic enantioselective vinylation of carbonyl enolates is still highly challenging and limited in substrate scope and, moreover, methods for the construction of quaternary stereocenters are very rare.^{12,14} Even more scarce and far less established are catalytic enantioselective carboxylations (Scheme 1C).¹⁵

As a result, we focused our attention on the catalytic oxidative scission of two carbons from the tail of an allyl unit in order to render such groups as carboxylic acid synthesis equivalents (Scheme 2). Herein, we present the results of that study and provide illustrative examples of this new method in the context of high value and unusual amino acid synthesis.

RESULTS AND DISCUSSION

After exploring a variety of transition metal catalysts known for alkene isomerization (iridium, rhodium, palladium, ruthenium; for details see the Supporting Information), we found that ruthenium catalysts performed best and were amenable to further oxidative catalysis (Scheme 2).

In particular, the commercially available Grubbs second generation catalyst **1a** (Figure 2) under Nishida's conditions¹⁶ was highly chemoselective for alkene isomerization and displayed good conversion (>90%) without noticeable side reactions. Moreover, we discovered that the in situ formed Ru-H complex¹⁷ **1b**, after solvent exchange, can be oxidized with NaIO₄ to an oxidized ruthenium species,¹⁸ which is capable of catalyzing subsequent oxidation reactions (*e.g.* oxidative cleavage of alkenes, Scheme 2).¹⁹ It has to be reinforced at this point that we do not add a new external ruthenium source for the second step. Instead, the crude transition metal catalyst from the previous isomerization step is modified in situ and reused for the catalytic oxidation reactions. Moreover, the only operation between the two steps is evaporation of the solvent from the isomerization reaction

(toluene for **1a**, acetone for **2**) followed by dissolution of the crude reaction mixture in the solvent mixture used for oxidation (CCl₄, MeCN, H₂O).

Even though NaIO₄ mediated oxidations of ruthenium alkylidene complexes and their use in sequential and tandem catalysis^{19b,20} have been described previously (*e.g.* RCM/dihydroxylation),²¹ the modification and multiple use¹³ of a ruthenium-hydride complex¹⁷ **1b** (derived from precatalyst **1a**) or a ruthenium phosphine-imidazole complex²² **2** in an isomerization/oxidation sequence was not known, until now (Figure 2).

Hence, chiral homoallylic amine **3**, which was readily synthesized via diastereoselective allylation of Ellman's sulfinimine,^{5e} was subjected to the optimized conditions using Grubbs catalyst **1a** giving the isomerized alkene in 98% conversion (Scheme 3A). After oxidation of the crude catalyst, an alkene cleavage/sulfinamide oxidation duet²³ took place furnishing Bus-protected²⁴ *D*-*tert*-leucine (**4**) in 72% yield over 2 steps, notably without racemization (99% *ee*). The Bus protected amino acid **4** can be employed directly for a peptide coupling as reported by Hanessian,²⁴ or the Bus group is readily cleaved under acidic conditions to afford *D*-*tert*-leucine (**5**) in 96% yield (98% *ee*) after ion exchange chromatography.

Alternatively, by leaving out the olefin isomerization, sulfinamide **3** was subjected to a similar alkene cleavage/ sulfinamide oxidation sequence with a catalytic amount of RuCl₃ hydrate giving Bus-protected β-amino acid **6** in 93% yield (Scheme 3B). After deprotection and ion exchange chromatography, (*S*)-β-neopentylglycine (**7**) was obtained in 91% yield and 98% *ee*. Benzoyl protected amine **8**, which is accessible in enantiopure form using Schaus' allylboration,²⁵ performed equally well in our sequential ruthenium catalysis, affording carboxylic acid **9** in 88% yield over 2 steps (Scheme 3C). Benzoyl deprotection with aqueous HCl in methanol provided racemic *tert*-leucine (**5**) in 57% yield.

The sequential ruthenium catalysis was then used for an enantioselective total synthesis of levetiracetam (**12**), the active pharmaceutical ingredient of the antiepileptic medicine Keppra® (Scheme 3D).²⁶ The synthesis commenced from homoallylic amide **10**, which was prepared in four steps from commercially available propionaldehyde and Ellman's auxiliary^{5e} (see the Supporting Information for details). Sequential ruthenium catalysis of alkene **10** with Grubbs catalyst **1a** provided access to carboxylic acid **11** in 62% yield over two steps. Amidation of **11** was achieved via the corresponding mixed anhydride and reaction with ammonium hydroxide as described previously by Sánchez.²⁷ Levetiracetam (**12**) was isolated in 67% yield (>98% *ee*) and, after one recrystallization, was enriched to excellent enantiopurity (>99.9% *ee*).

We next applied our sequential ruthenium catalysis conditions to α-quaternary lactams (Scheme 4), which were readily available in enantiopure form using palladium-catalyzed decarboxylative allylic alkylation.^{8a,28} The unprotected methyl- and ethyl-substituted lactams **13** and **14** were treated with a catalytic amount of Grubbs catalyst **1a** and the internal alkene was subsequently cleaved to give the crude carboxylic acids. A Curtius rearrangement²⁹ then furnished isocyanates **15** and **16** in 27% and 47% yield over 3 steps, respectively.³⁰ Likewise, we found that 2 mol% of Grotjahn's catalyst²² (**2**, Figure 2)

worked equally well³¹ for the ruthenium-catalyzed isomerization/oxidation sequence of lactam **14** to give, after Curtius rearrangement, isocyanate **16** in a comparable 52% yield over 3 steps.³² Hydrolysis of the isocyanate and the amide bond of **15** and **16** were achieved under acidic conditions to give access to enantiopure (*R*)- α -methylornithine³³ (**17**) and (*R*)- α -ethylornithine³⁴ (**18**) in 61% and 95% yield, respectively. The latter has been synthesized for the first time as a single enantiomer.³⁴ Biologically, both α -alkyl ornithine analogs are known to be ornithine decarboxylase inhibitors.^{33a,34}

Treatment of caprolactam **19** and glutarimide **22** with catalyst **1a** under our optimized conditions gave, after Curtius rearrangement, hydantoin **20** and isocyanate **23** in 65% and 34% yield over 3 steps, respectively. Anti-Bredt bicycle^{35–37} **20** results from an intramolecular cyclization of the lactam NH to the isocyanate. Its structure was unambiguously confirmed by X-ray crystallography (see the Supporting Information). Subsequent hydrolysis of **20** and **23** with aqueous HCl furnished (*R*)- α -methyllysine^{33d} (**21**) and (*R*)- α -methylglutamic acid^{33c,38} (**24**), respectively, in excellent yields (92% and 99%). Given the recent availability of α -quaternary lactams and imides,²⁸ it is possible to envision the synthesis of a wide range of α -substituted amino acid derivatives for a multitude of applications.

The enantioenriched carboxylic acid **25**, obtained by our Ru-catalyzed isomerization oxidation method on lactam **14** (Scheme 4), is not only an intermediate in Padwa's racemic synthesis of desacetoxy-4-oxo-6,7-dihydrovindoro-sine³⁹ (**29**), but can also be used for the synthesis of Cbz-protected α -amino lactam **26** (98% *ee*) by trapping the intermediate isocyanate **16** with benzyl alcohol following the Curtius rearrangement (Scheme 5). Hydrogenolysis of the Cbz group gave amino lactam **27** in quantitative yield, which renders Knabe's racemic synthesis of 3-ethyl thalidomide⁴⁰ (**30**) enantioselective. Reduction of lactam **27** with LiAlH₄, followed by precipitation as the bishydrochloride salt furnished chiral diamine **28** in 89% yield. The racemic, mono-Boc protected version of **28** was used recently by Nishio *et al.*⁴¹ for the synthesis of dipeptidyl peptidase IV (DPP-4) inhibitors.

CONCLUSIONS

In summary, we have developed a highly efficient ruthenium catalyzed isomerization/oxidation sequence, which enabled the syntheses of challenging unnatural amino acids such as *D*-tert-leucine (**5**), (*S*)- β -neopentylglycine (**7**), (*R*)- α -methyl- and ethylornithine (**17** and **18**), (*R*)- α -methyllysine (**21**) and (*R*)- α -methylglutamic acid (**24**). The reaction sequence performs well with not only ruthenium-hydride complex **1b** (derived from Grubbs catalyst **1a**), but also with the less common Grotjahn catalyst **2**. We found that both isomerization catalysts **1b** and **2** can be used to perform one or several subsequent oxidation steps after NaIO₄ treatment of the crude reaction mixtures. To demonstrate the utility of our method, we have completed an enantioselective total synthesis of the antiepileptic drug levetiracetam (**12**) and enantioselective formal syntheses of a vindorosine derivative **29** and of (*R*)-3-ethyl thalidomide (**30**). Given the importance and ubiquity of the amino acid subunit in organic chemistry, we believe that our method will inspire many creative permutations and applications. Further usages of the method are currently under investigation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Dedicated to Professor Albert Padwa on the occasion of his 80th birthday. The authors wish to thank NIH-NIGMS (R01GM080269), Amgen, the Gordon and Betty Moore Foundation and Caltech for financial support. M.L. thanks the Swiss National Science Foundation (SNSF) for a postdoctoral fellowship (P2EZP2_148751). Dr. Scott Virgil and the Caltech Center for Catalysis and Chemical Synthesis are acknowledged for the generous donation of catalyst **2** and Materia Inc. for the donation of catalyst **1a**. The authors thank Dr. Michael Takase and Larry Henling for X-ray structural determinations. The Hsieh-Wilson group is acknowledged for nanopure water and the Dougherty group for using their freeze-drying equipment. Lukas Hilpert, Kyle Virgil and Katerina Korch are thanked for experimental assistance. Beau P. Pritchett is gratefully acknowledged for recording analytical data and for proofreading this manuscript.

References

1. For the definition of sequential transformations see: Tietze LF, Beifuss U. *Angew Chem Int Ed Engl.* 1993; 32:131.
2. (a) North, M. *Sustainable Catalysis: Without Metals or Other Endangered Elements, Part 1.* North, M., editor. The Royal Society of Chemistry; Cambridge: 2016. p. 1-2.(b) Holzwarth MS, Plietker B. *ChemCatChem.* 2013; 5:1650.(c) Roeder, MH., Eigenbrodt, BC., Paul, JJ. *Catalysis for Sustainability: Goals, Challenges, and Impacts.* Umile, TP., editor. CRC Press; Boca Raton: 2016. p. 149-176.
3. (a) Carreira, EM., Yamamoto, H., editors. *Comprehensive Chirality.* Vol. 9. Elsevier; Amsterdam: 2012. *Industrial Applications of Asymmetric Synthesis*; p. 1-506.(b) Brown DG, Boström J. *J Med Chem.* 2016; 59:4443. [PubMed: 26571338]
4. (a) Carreira, EM., Kvaerno, L. *Classics in Stereoselective Synthesis.* Vol. Chapter 5. Wiley-VCH; Weinheim: 2008. p. 153-186.(b) Carreira, EM., Kvaerno, L. *Classics in Stereoselective Synthesis.* Vol. Chapter 14. Wiley-VCH; Weinheim: 2008. p. 457-482.
5. For selected seminal publications of nucleophilic allylation see: Hosomi A, Sakurai H. *Tetrahedron Lett.* 1976; 17:1295. Brown HC, Jadhav PK. *J Am Chem Soc.* 1983; 105:2092. Roush WR, Walts AE, Hoong LK. *J Am Chem Soc.* 1985; 107:8186. Keck GE, Tarbet KH, Geraci LS. *J Am Chem Soc.* 1993; 115:8467. Liu G, Cogan DA, Ellman JA. *J Am Chem Soc.* 1997; 119:9913. Cogan DA, Liu G, Ellman J. *Tetrahedron.* 1999; 55:8883. Kinnaird JWA, Ng PY, Kubota K, Wang X, Leighton JL. *J Am Chem Soc.* 2002; 124:7920. [PubMed: 12095334] Kim IS, Ngai MY, Krische MJ. *J Am Chem Soc.* 2008; 130:6340. [PubMed: 18444616] Kim IS, Ngai MY, Krische MJ. *J Am Chem Soc.* 2008; 130:14891. [PubMed: 18841896] Beeson TD, Mastracchio A, Hong JB, Ashton K, MacMillan DWC. *Science.* 2007; 316:582. [PubMed: 17395791] Vieira EM, Snapper ML, Hoveyda AH. *J Am Chem Soc.* 2011; 133:3332. [PubMed: 21341657] Silverio DL, Torker S, Pilyugina T, Vieira EM, Snapper ML, Haefner F, Hoveyda AH. *Nature.* 2013; 494:216. [PubMed: 23407537]
6. For recent reviews see: Denmark SE, Fu J. *Chem Rev.* 2003; 103:2763. [PubMed: 12914480] Bower JF, Kim IS, Patman RL, Krische MJ. *Angew Chem Int Ed.* 2009; 48:34. Yus M, González-Gómez JC, Foubelo F. *Chem Rev.* 2011; 111:7774. [PubMed: 21923136]
7. (a) Grignard V. *C R Hebd Acad Sci.* 1900; 130:1322.(b) Hutchison DA, Beck KR, Benkeser RA, Grutzner JB. *J Am Chem Soc.* 1973; 95:7075.(c) Benkeser RA. *Synthesis.* 1971:347.
8. For selected references of electrophilic allylation see: Behenna DC, Stoltz BM. *J Am Chem Soc.* 2004; 126:15044. [PubMed: 15547998] Krautwald S, Sarlah D, Schafroth MA, Carreira EM. *Science.* 2013; 340:1065. [PubMed: 23723229] Liu WB, Reeves CM, Virgil SC, Stoltz BM. *J Am Chem Soc.* 2013; 135:10626. [PubMed: 23829704] Pupo G, Properzi R, List B. *Angew Chem Int Ed.* 2016; 55:6099. For selected reviews see: Trost BM, Van Vranken DL. *Chem Rev.* 1996; 96:395. [PubMed: 11848758] Trost BM, Crawley ML. *Chem Rev.* 2003; 103:2921. [PubMed: 12914486] Hartwig JF, Stanley LM. *Acc Chem Res.* 2010; 43:1461. [PubMed: 20873839] Hong AY, Stoltz BM. *Eur J Org Chem.* 2013:2745. Zhuo CX, Zheng C, You SL. *Acc Chem Res.* 2014; 47:2558. [PubMed: 24940612]

9. (a) Tsuji J, Takahashi H, Morikawa M. *Tetrahedron Lett.* 1965; 6:4387.(b) Trost BM, Fullerton TJ. *J Am Chem Soc.* 1973; 95:292.
10. For examples of tin-free radical allylations see: Quiclet-Sire B, Zard SZ. *J Am Chem Soc.* 1996; 118:1209.Schaffner AP, Renaud P. *Angew Chem Int Ed.* 2003; 42:2658.Debien L, Quiclet-Sire B, Zard SZ. *Acc Chem Res.* 2015; 48:1237. [PubMed: 25905563]
11. Keck GE, Yates JB. *J Am Chem Soc.* 1982; 104:5829.
12. Quasdorf KW, Overman LE. *Nature.* 2014; 516:181. [PubMed: 25503231]
13. For selected examples of one-pot catalysis with 1a and 2 using a second catalyst, see: Baader S, Podsiadly PE, Cole-Hamilton DJ, Goossen LJ. *Green Chem.* 2014; 16:4885.Dobereiner GE, Erdogan G, Larsen CR, Grotjahn DB, Schrock RR. *ACS Catal.* 2014; 4:3069.Higman CS, De Araujo MP, Fogg DE. *Catal Sci Technol.* 2016; 6:2077.
14. (a) Chieffi A, Kamikawa K, Åhman J, Fox JM, Buchwald SL. *Org Lett.* 2001; 3:1897. [PubMed: 11405739] (b) Taylor AM, Altman RA, Buchwald SL. *J Am Chem Soc.* 2009; 131:9900. [PubMed: 19580273] (c) Liu Y, Virgil SC, Grubbs RH, Stoltz BM. *Angew Chem Int Ed.* 2015; 54:11800.
15. The only example we could find for a homogeneous carboxylation using CO₂ is a nickel-catalyzed asymmetric carboxylative cyclization of bis-1,3-dienes: Takimoto M, Nakamura Y, Kimura K, Mori M. *J Am Chem Soc.* 2004; 126:5956. [PubMed: 15137747]
16. (a) Arisawa M, Terada Y, Nakagawa M, Nishida A. *Angew Chem Int Ed.* 2002; 41:4732.(b) Arisawa M, Terada Y, Takahashi K, Nakagawa M, Nishida A. *J Org Chem.* 2006; 71:4255. [PubMed: 16709069]
17. (a) Trnka TM, Morgan JP, Sanford MS, Wilhelm TE, Scholl M, Choi TL, Ding S, Day MW, Grubbs RH. *J Am Chem Soc.* 2003; 125:2546. [PubMed: 12603143] (b) Dinger MB, Mol JC. *Eur J Inorg Chem.* 2003:2827.(c) Hong SH, Day MW, Grubbs RH. *J Am Chem Soc.* 2004; 126:7414. [PubMed: 15198568]
18. This oxidized ruthenium species might be similar to RuO₄. However, the exact nature has not been unambiguously established.
19. For reviews about RuO₄ mediated oxidations see: Gore ES. *Platinum Metals Rev.* 1983; 27:111.Piccialli V. *Molecules.* 2014; 19:6534. [PubMed: 24853716]
20. For reviews about sequential and tandem Ru catalysis see: Alcaide B, Almendros P. *Chem Eur J.* 2003; 9:1258. [PubMed: 12645014] Alcaide B, Almendros P, Luna A. *Chem Rev.* 2009; 109:3817. [PubMed: 19572654]
21. For the use of Ru complexes in sequential and tandem catalysis coupled to an oxidation step see: Louie J, Bielawski CW, Grubbs RH. *J Am Chem Soc.* 2001; 123:11312. [PubMed: 11697983] Beligny S, Eibauer S, Maechling S, Blechert S. *Angew Chem Int Ed.* 2006; 45:1900.Scholte AA, An MH, Snapper ML. *Org Lett.* 2006; 8:4759. [PubMed: 17020296] Neisius NM, Plietker B. *J Org Chem.* 2008; 73:3218. [PubMed: 18358049] Schmidt B, Krehl S. *Chem Commun.* 2011; 47:5879.Kato H, Ishigame T, Oshima N, Hoshiya N, Shimawaki K, Arisawa M, Shuto S. *Adv Synth Catal.* 2011; 353:2676.Schmidt B, Krehl S, Hauke S. *J Org Chem.* 2013; 78:5427. [PubMed: 23641707] Dornan PK, Wickens ZK, Grubbs RH. *Angew Chem Int Ed.* 2015; 54:7134.Malik M, Ceborska M, Witkowski G, Jarosz S. *Tetrahedron: Asymmetry.* 2015; 26:29.Dornan PK, Lee D, Grubbs RH. *J Am Chem Soc.* 2016; 138:6372. [PubMed: 27133576]
22. (a) Grotjahn DB, Larsen CR, Gustafson JL, Nair R, Sharma A. *J Am Chem Soc.* 2007; 129:9592. [PubMed: 17636924] (b) Erdogan G, Grotjahn DB. *J Am Chem Soc.* 2009; 131:10354. [PubMed: 19585995] (c) Larsen CR, Grotjahn DB. *J Am Chem Soc.* 2012; 134:10357. [PubMed: 22702432] (d) Erdogan G, Grotjahn DB. *Org Lett.* 2014; 16:2818. [PubMed: 24811148]
23. For this classification of tandem reactions see: Jones AC, May JA, Sarpong R, Stoltz BM. *Angew Chem Int Ed.* 2014; 53:2556.
24. Hanessian S, Wang X. *Synlett.* 2009:2803.
25. Lou S, Moquist PN, Schaus SE. *J Am Chem Soc.* 2007; 129:15398. [PubMed: 18020334]
26. Lyseng-Williamson KA. *Drugs.* 2011; 71:489. [PubMed: 21395360]
27. Boschi F, Camps P, Comes-Franchini M, Muñoz-Torrero D, Ricci A, Sánchez L. *Tetrahedron: Asymmetry.* 2005; 16:3739.

28. (a) Behenna DC, Mohr JT, Sherden NH, Marinescu SC, Harned AM, Tani K, Seto M, Ma S, Novák Z, Krout MR, McFadden RM, Roizen JL, Enquist JA, White DE, Levine SR, Petrova KV, Iwashita A, Virgil SC, Stoltz BM. *Chem Eur J*. 2011; 17:14199. [PubMed: 22083969] (b) Behenna DC, Liu Y, Yurino T, Kim J, White DE, Virgil SC, Stoltz BM. *Nat Chem*. 2012; 4:130.
29. Similar stereoselective Curtius rearrangements have been used previously to prepare α -tertiary amines, isocyanates and α -quaternary amino acids: Leuser H, Perrone S, Liron F, Kneisel FF, Knochel P. *Angew Chem Int Ed*. 2005; 44:4627. Iosub V, Haberl AR, Leung J, Tang M, Vembaiyan K, Parvez M, Back TG. *J Org Chem*. 2010; 75:1612. [PubMed: 20131857] Banerjee S, Wiggins WJ, Geoghegan JL, Anthony CT, Woltering EA, Masterson DS. *Org Biomol Chem*. 2013; 11:6307. [PubMed: 23942875]
30. It should be noted that the isocyanates were stable to purification by column chromatography and could be stored as solids under high vacuum. However, upon exposure to air moisture, they decomposed and polymerized quickly (within hours).
31. The major difference between the reactivity of catalyst **1b** and **2** is that ruthenium hydride complex **1b** is highly selective for the isomerization of just one position to give the 2-ene product. In contrast, catalyst **2** is more reactive and less selective, which may lead to over isomerization for substrates containing a proton in position 4 of the allyl group such as for **3**, **8** and **10**. This difference in reactivity is in agreement with a lower catalyst loading used for **2** (2 mol%) compared to **1b** (5 mol%). Since we had large quantities of **1a** available in our lab and catalyst **2** was rather expensive at the time (commercially available from Strem Chemicals and abcr GmbH, CAS 930601-66-4), we preferred to use **1a** for Scheme 4. However, similar yields are expected for both catalysts **1a** and **2** as we have shown for substrate **14**.

32. When we used forcing conditions for the second step with catalyst **2** (5 and 10 mol%), we observed a “lactam oxidation/alkene cleavage/decarboxylation/hydroxylation” reaction quartet for **32**. The tertiary alcohol **33** was isolated in 16% and 32% yield over 2 steps, respectively. Unfortunately, the reaction led to a racemic product.
33. (a) Bey P, Danzin C, Van Dorsselaer V, Mamont P, Jung M, Tardif C. *J Med Chem*. 1978; 21:50. [PubMed: 619149] (b) Kirihata M, Mihara S, Ichimoto I, Ueda H. *Agric Biol Chem*. 1978; 42:185. (c) Yamamoto Y, Kirihata M, Ichimoto I, Ueda H. *Agric Biol Chem*. 1985; 49:1761. (d) Gander-Coquoz M, Seebach D. *Helv Chim Acta*. 1988; 71:224.
34. For the only racemic synthesis see: Abdel-Monem MM, Newton NE, Ho BC, Weeks CE. *J Med Chem*. 1975; 18:600. [PubMed: 1151975]
35. For a recent review on the synthesis and reactivity of bridged lactams, see: Szostak M, Aubé J. *Chem Rev*. 2013; 113:5701. [PubMed: 24490625]
36. For previous studies from our group in the topic of twisted lactams, see: Tani K, Stoltz BM. *Nature*. 2006; 441:731. [PubMed: 16760973] Ly T, Krout M, Pham DK, Tani K, Stoltz BM, Julian RR. *J Am Chem Soc*. 2007; 129:1864. [PubMed: 17256939] Liniger M, VanderVelde DG, Takase MK, Shahgholi M, Stoltz BM. *J Am Chem Soc*. 2016; 138:969. [PubMed: 26713861]
37. A few 1,7-diazabicyclo[4.2.1]nonane-8,9-dione derivatives are known: Akhtar MS, Brouillette WJ, Waterhous DV. *J Org Chem*. 1990; 55:5222. Brouillette WJ, Jestkov VP, Brown ML, Akhtar MS, DeLorey TM, Brown GB. *J Med Chem*. 1994; 37:3289. [PubMed: 7932556] Knaup G. *Ger Offen*. 2001:DE10020818.
38. (a) Aebi JD, Seebach D. *Helv Chim Acta*. 1985; 68:1507. (b) Acher F, Azerad R. *Tetrahedron: Asymmetry*. 1994; 5:731. (c) Obrecht D, Bohdal U, Daly J, Lehmann J, Schönholzer P, Müller K. *Tetrahedron*. 1995; 51:10883. (d) Sawamura M, Nakayama Y, Tang WM, Ito Y. *J Org Chem*. 1996; 61:9090. (e) Chinchilla R, Galindo N, Nájera C. *Synthesis*. 1999:704. (f) Abellán T, Chinchilla R, Galindo N, Nájera C, Sansano JM. *J Heterocyclic Chem*. 2000; 37:467.
39. Padwa A, Price AT. *J Org Chem*. 1998; 63:556. [PubMed: 11672045]
40. Knabe J, Omlor G. *Arch Pharm*. 1989; 322:499.

41. Nishio Y, Kimura H, Sawada N, Sugaru E, Horiguchi M, Ono M, Furuta Y, Sakai M, Masui Y, Otani M, Hashizuka T, Honda Y, Deguchi J, Nakagawa T, Nakahira H. *Bioorg Med Chem*. 2011; 19:5490. [PubMed: 21865048]

Figure 1.
General modes for the introduction of allyl groups.

Figure 2.

Identified ruthenium catalysts for olefin isomerization/ oxidation sequences – An in situ formed ruthenium-hydride complex **1b** derived from Grubbs second generation catalyst (**1a**) and Grotjahn's catalyst (**2**).

A. This research: allylation + isomerization/oxidation sequence ($M_1=M_2$) **B. Asymmetric vinylation + oxidation** **C. Asymmetric carboxylation** **Scheme 1.**

Sequences and methods for the introduction of chiral carboxylic acid groups.

Scheme 2.

Ruthenium-catalyzed two-carbon truncation of allyl groups to carboxylic acids.

Scheme 3.

a) 1. Grubbs **1a** (5 mol%), VTMS, toluene, reflux, 21 h, 98% conv., *E/Z* 4.4:1; 2. NaIO₄, CCl₄, MeCN, H₂O, 23°C, 2.5 d, 72% yield over 2 steps, 99% ee; b) 1. TfOH, CH₂Cl₂, 0°C, 2.5 h; 2. IEC, 96% yield, 98% ee; c) RuCl₃•H₂O (5 mol%), NaIO₄, CCl₄, MeCN, H₂O, 23°C, 16 h, 93% yield; d) 1. TfOH, CH₂Cl₂, 0°C→23°C, 2 d; 2) IEC, 91% yield, 98% ee; e) 1. Grubbs **1a** (5 mol%), VTMS, toluene, 128°C, 16 h, 97% conv., *E/Z* 4:1; 2. NaIO₄, CCl₄, MeCN, H₂O, 23°C, 22 h, 88% yield over 2 steps; f) 1. 4 M aq. HCl, MeOH, reflux, 24 h; 2. IEC, 57% yield; g) 1. Grubbs **1a** (5 mol%), VTMS, toluene, 128°C, 18 h, 92% conv., *E/Z* 4.5:1; 2. NaIO₄, CCl₄, MeCN, H₂O, 23°C, 24 h, 62% yield over 2 steps; h) ClCO₂Et, NEt₃, THF, then NH₄OH, 0°C→23°C, 19 h, 67% yield, >98% ee. IEC=ion exchange chromatography, VTMS=vinyloxy trimethylsilane.

Scheme 4.

a) **15**: 1. Grubbs **1a** (5 mol%), VTMS, toluene, 130°C, 18 h, 88% conv.; 2. NaIO₄, CCl₄, MeCN, H₂O, 23°C; 3. DPPA, NEt₃, MeCN, 0°C→65°C, 3 h, 27% yield over 3 steps; **16**: 1. Grubbs **1a** (5 mol%), VTMS, toluene, 125°C, 16 h, 96% conv. or Grotjahn **2** (2 mol%), acetone-d₆, 70°C, 63 h, 95% conv.; 2. NaIO₄, CCl₄, MeCN, H₂O, 23°C; 3. DPPA, NEt₃, MeCN, 0°C→65°C, 47% yield over 3 steps (with **1a**) and 52% yield over 3 steps (with **2**); b) **17**: 1. 4 M aq. HCl, 1,4-dioxane, 120°C, 12 h; 2. IEC, 61% yield; **18**: 1. 2 M aq. HCl, THF, reflux, 24 h; 2. IEC, 95% yield; c) 1. Grubbs **1a** (5 mol%), VTMS, toluene, 129°C, 21 h, 96% conv., 2. NaIO₄, CCl₄, MeCN, H₂O, 23°C, 24 h; 3. DPPA, NEt₃, MeCN, 0°C→65°C, 3 h, 65% yield over 3 steps; d) 1. 4 M aq. HCl, dioxane, reflux, 18 h; 2. IEC, 92% yield; e) 1. Grubbs **1a** (5 mol%), VTMS, toluene, 129°C, 21 h, 93% conv.; 2. NaIO₄, CCl₄, MeCN, H₂O, 23°C, 25 h; 3. DPPA, NEt₃, MeCN, 0°C→65°C, 3 h, 34% yield over 3 steps; f) 1. 4 M aq. HCl, dioxane, reflux, 18 h; 2. IEC, 99% yield. DPPA=diphenyl phosphoryl azide, IEC=ion exchange chromatography, VTMS=vinyloxy trimethylsilane.

Scheme 5.

a) DPPA, NEt₃, DCE, 23°C→reflux, 5 h, then BnOH, reflux, 38 h, 29% yield, 98% ee; b) H₂, Pd/C, MeOH, 23°C, 4 h, >99% yield; c) LiAlH₄, THF, 0°C→reflux, 24 h, then HCl/dioxane, 89% yield. DCE=1,2-dichloroethane, DPPA= diphenyl phosphoryl azide.